JNJ 17166864

Drug Profile

JNJ 17166864

Latest Information Update: 30 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antiallergics; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation; Seasonal allergic rhinitis

Most Recent Events

  • 30 Sep 2015 No recent reports on development identified - Phase-I/II for Seasonal allergic rhinitis in USA (Intranasal)
  • 30 Sep 2015 No recent reports on development identified - Preclinical for Inflammation in USA (Topical)
  • 21 May 2008 Preclinical trials in Inflammation in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top